Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0T3CE
|
|||
Former ID |
DIB016439
|
|||
Drug Name |
SUPER-LEU-DOX
|
|||
Synonyms |
CPI-0004; CPI-0004Na; CPI-004Na; DTS-201; TAP-doxorubicin; TSP-doxorubicin; Phthacene-5,12-dione sodium salt; N-[N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl]daunorubicin sodium salt; (8S,10S)-10-[3-[N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy]-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrona
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 2 | [1] | |
Company |
Diatos SA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260) | |||
REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.